enow.com Web Search

Search results

  1. Results from the WOW.Com Content Network
  2. Roche joins race for obesity drugs with $2.7 billion Carmot deal

    www.aol.com/news/roche-enters-obesity-drug...

    Roche shares opened up 1.75%, hitting a six-week high on optimism that the weight-loss market will accommodate many rivals. ... Roche said. Carmot's employees will join Roche's pharmaceuticals ...

  3. Roche targets more than $3 billion in annual obesity sales - AOL

    www.aol.com/news/roche-targets-more-3-billion...

    Roche said on Monday that three early-stage obesity and diabetes drug candidates from its acquisition of Carmot Therapeutics have the combined potential of more than 3 billion Swiss francs ($3.6 ...

  4. Roche - Wikipedia

    en.wikipedia.org/wiki/Roche

    Roche acquired Syntex in 1994, and Chugai Pharmaceuticals in 2002. Oseltamivir an antiviral drug used to combat influenza. Roche is the only drug company authorized to manufacture the drug, which was discovered by Gilead Sciences. Roche purchased the rights to the drug in 1996, and in 2005, settled a royalty dispute, agreeing to pay Gilead ...

  5. Scott Foresman - Wikipedia

    en.wikipedia.org/wiki/Scott_Foresman

    In February 2019, Pearson spun off its US-based K-12 courseware business, which was renamed Pearson K12 Learning. The newly independent K-12 publishing company later rebranded as Savvas Learning Company in May 2020. [11] The trademark registration for Scott Foresman is now owned by Savvas Learning Company. [12]

  6. Roche shares knocked by concern over side effects in obesity ...

    www.aol.com/news/roche-shares-drop-side-effects...

    Side effects data that Roche released on Monday on another early Carmot project, injection CT-388, had also weighed on its shares, for a 5.4% decline so far this week.

  7. Regeneron Pharmaceuticals - Wikipedia

    en.wikipedia.org/wiki/Regeneron_Pharmaceuticals

    Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York.The company was founded in 1988. [2] Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its name, the company branched out into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a ...

  8. Roche to fast-track weight loss drugs to compete with rivals ...

    www.aol.com/news/roche-fast-track-weight-loss...

    Roche is among a growing number of would-be rivals to Novo and Eli Lilly, whose weight-loss injections have been in feverish demand, with experts boosting their sales forecasts for such treatments ...

  9. Syntex - Wikipedia

    en.wikipedia.org/wiki/Syntex

    Syntex agreed to be acquired by the Roche group in May 1994. [6] After the acquisition closed, Roche downsized Syntex's research and development facilities in the Stanford Research Park and finally shut down what was left of Syntex in September 2008. [7] In 2011, VMware moved into the former Syntex campus in Palo Alto. [8]